The FDA's Priority Review Voucher (PRV) program is a rare-disease-development incentive that awards a transferable voucher to the sponsor of any FDA-approved therapy for a designated rare pediatric disease, tropical disease, or medical countermeasure. The voucher can be used to accelerate FDA review of a future NDA or BLA submission (from standard 10-12 months down to priority 6 months) or sold to another drug developer on the secondary market.
PRV secondary-market pricing has ranged from $67 million (the low, 2015 to Sanofi from Retrophin) to $350 million (the high, 2015 to AbbVie from United Therapeutics). Recent transactions: Arrowhead Pharmaceuticals sold a PRV for $215 million cash in connection with the plozasiran familial chylomicronemia syndrome approval earlier in 2026, and Ionis Pharmaceuticals received a PRV alongside the September 3, 2026 Zanvastro (zilganersen) approval for Alexander disease. Historical average voucher price sits in the $100-200 million range.
Program economics: PRVs materially shift the commercial calculus for ultra-rare pediatric disease programs where the addressable patient population alone would not economically justify development. The Consolidated Appropriations Act 2026, signed February 3, 2026, reauthorized the Rare Pediatric Disease PRV program through September 2029 via the Mikaela Naylon Give Kids a Chance Act — materially reducing the sunset risk that had shadowed rare-disease commercial modeling in 2025. Since program launch in 2012, 63 PRVs have been awarded across 47 rare diseases from Duchenne muscular dystrophy to hemophilia A, including recipients Kalydeco (Vertex), Spinraza (Biogen), Zolgensma (Novartis), plozasiran (Arrowhead, 2026), and Zanvastro (Ionis, September 2026). Stories here cover PRV grants, secondary-market transactions, program reauthorization debate, and how vouchers shape rare-disease program economics. See [[rare-pediatric-disease]], [[fda-accelerated-approval]], and [[orphan-drug]] for adjacent threads.
Several analysts raised their Ultragenyx price targets on Friday, September 18, 2026, a day after the FDA's standard full approval of FAYUVI for the neurologic manifestations of Sanfilippo syndrome type A (MPS IIIA) in children. Cantor Fitzgerald moved to $39 from $33 with an Overweight rating, raised its probability of success to 100% from 90%, and valued the MPS IIIA opportunity at about $12 to $13 per share; Canaccord Genuity moved to $39 from $37 (Buy), Morgan Stanley to $20 from $18 (Equal Weight), and Citi to $32. Cantor also estimated that the priority review voucher Ultragenyx received with the approval, together with another voucher the company already holds, could bring in about $400 million if sold. Ultragenyx expects FAYUVI to be available to ship to qualified treatment centers within 30 to 60 days.
A factual correction on the Rare Pediatric Disease Priority Review Voucher (PRV) program timeline: the Consolidated Appropriations Act 2026, signed by President Trump on February 3, 2026, reauthorized the RPD PRV program through September 2029, materially reducing the sunset risk that had shadowed rare-disease commercial modeling. The reauthorization was passed via the Mikaela Naylon Give Kids a Chance Act embedded in the CAA and covers all rare pediatric disease sponsors submitting NDAs and BLAs during the reauthorization window. Since program launch in 2012, 63 RPD PRVs have been awarded across 47 rare diseases from Duchenne muscular dystrophy to hemophilia A. Recent PRV secondary-market pricing has ranged from $67 million (2015 low) to $350 million (2015 high), with recent transactions clustered in the $100-250 million range. Arrowhead sold a PRV for $215 million alongside the plozasiran FCS approval earlier in 2026, and Ionis Pharmaceuticals received a PRV alongside the September 3 Zanvastro (zilganersen) Alexander disease approval. The reauthorization also amends the Orphan Drug Act to clarify that orphan drug exclusivity applies to the FDA's approved use or indication within a rare disease rather than the entire rare disease.
Ionis Pharmaceuticals (NASDAQ: IONS) announced Thursday September 3, 2026 FDA approval of Zanvastro (zilganersen, an intrathecally-administered antisense oligonucleotide designed to reduce glial fibrillary acidic protein / GFAP production) for the treatment of Alexander disease in pediatric and adult patients. The approval is the first-ever disease-modifying therapy for Alexander disease, an ultra-rare autosomal dominant neurodegenerative disorder caused by GFAP gene mutations that presents in infancy through adulthood with progressive motor and cognitive decline. Approval landed 19 days ahead of the September 22, 2026 PDUFA target action date. In the registrational trial, walking speed stayed stable in Zanvastro-treated patients while control patients saw a 33% decline. FDA granted Ionis a Rare Pediatric Disease Priority Review Voucher (PRV) alongside the approval; PRVs have historically sold for $150-350 million on secondary markets. Zanvastro follows Ionis's Wainua (eplontersen) commercial franchise for hereditary transthyretin amyloid polyneuropathy and lands after the August 28 CARDIO-TTRansform ATTR-CM Phase 3 primary endpoint miss for the same molecule.
The Rare Pediatric Disease Priority Review Voucher (PRV) granted to Ionis Pharmaceuticals (NASDAQ: IONS) alongside the Zanvastro (zilganersen) FDA approval Thursday September 3, 2026 for Alexander disease adds substantial commercial value to the launch economics. PRVs have historically sold for $150 to $350 million on the secondary market and can be transferred an unlimited number of times. Recent PRV transactions: Arrowhead Pharmaceuticals sold a PRV for $215 million cash in connection with the plozasiran FCS approval earlier in 2026; other recent PRV sales have priced in the $100-200 million range. Ionis has not yet disclosed plans for the PRV — the company can use it to accelerate FDA review of a future NDA/BLA submission (from standard 10-12 months to priority 6 months) or sell it to another drug developer. The PRV program has faced periodic legislative sunset threats and is currently authorized through December 2026; the incentive continues to drive investment into rare pediatric disease programs where the commercial market alone would not economically justify development.
Amylyx Pharmaceuticals (NASDAQ: AMLX) provided pre-launch commercial-readiness detail Tuesday September 1, 2026 as the company continues to advance toward NDA submission for avexitide (exendin-9-39, a GLP-1 receptor antagonist peptide) in post-bariatric hypoglycemia (PBH) following the August 18 Phase 3 LUCIDITY primary-endpoint hit (55% reduction in composite Level 2/3 hypoglycemic events, p=0.000003). Target NDA submission end of 2026; commercial launch preparation continues on schedule; and the company will use the upsized $500.2 million August 21 public offering to fund launch operations plus AMX0318 (long-acting follow-on peptide) IND-enabling studies. The Priority Review Voucher regime granted Arrowhead $215 million for plozasiran continues to shape the commercial economics of first-in-class peptide approvals in rare metabolic indications, and Amylyx is expected to be eligible if avexitide receives Breakthrough Therapy designation.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) disclosed the full terms of its Priority Review Voucher (PRV) acquisition first mentioned on the August 4, 2026 fiscal Q2 2026 conference call. Terms: $215 million paid to an undisclosed seller under an asset purchase agreement expected to close in fiscal Q4 2026. Applied to: the plozasiran (Redemplo) supplemental new drug application (sNDA) for severe hypertriglyceridemia (sHTG), planned for submission before end of 2026 following the July 23, 2026 Phase 3 SHASTA-3 and SHASTA-4 positive readouts (79% SHASTA-3 and 81% SHASTA-4 median triglyceride reductions at Month 12 versus approximately 27% for placebo, plus statistically significant reductions in acute pancreatitis events). Return projection: Arrowhead management projects a 3x return on the $215 million PRV investment by shifting the plozasiran sHTG commercial uptake curve forward by approximately four months (the PRV compresses FDA new drug application review from the standard 10-month timeline to a 6-month priority review timeline). PRVs are transferable FDA-issued regulatory instruments awarded to sponsors that develop drugs for rare pediatric diseases, tropical diseases, or specific medical countermeasures; recent secondary-market transactions have priced PRVs in the $100-250 million range depending on demand and pipeline urgency. Redemplo (plozasiran) was FDA-approved November 2025 for familial chylomicronemia syndrome; the sHTG indication would substantially expand the addressable patient population.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) confirmed on the Fiscal Q2 2026 conference call Tuesday August 4, 2026 that the company has acquired a Priority Review Voucher (PRV), a transferable FDA-issued voucher that provides the option to shorten a future FDA new drug application review from the standard 10-month timeline to a 6-month timeline. PRVs are issued to sponsors that develop drugs for rare pediatric diseases, tropical diseases, or specific medical countermeasures under FDA statutory authority; they are transferable and can be sold on the secondary market where recent transactions have priced PRVs in the $100-200 million range. Arrowhead did not disclose the specific candidate to which the PRV will be applied but the timing (following the July 23, 2026 Phase 3 SHASTA-3 and SHASTA-4 positive readouts for plozasiran/Redemplo in severe hypertriglyceridemia) suggests the voucher may support the sNDA filing planned before end of 2026 for the severe hypertriglyceridemia indication. Separately, REDEMPLO (plozasiran) prescription volume has approximately doubled over fiscal Q3 following the November 2025 FDA approval for familial chylomicronemia syndrome, with continued momentum into the current quarter. Arrowhead management expressed continued satisfaction with the launch trajectory approximately 8.5 months after initial approval.